Kala Bio (KALA) Accumulated Depreciation (2016 - 2025)
Kala Bio (KALA) posted Accumulated Depreciation of $869000.0 for Q4 2025, down 33.87% sequentially from $1.3 million in Q4 2024, and down 33.87% YoY from $1.3 million in Q4 2024.
Kala Bio (KALA) Accumulated Depreciation (2016 - 2025) Analysis & Trends
Kala Bio has reported Accumulated Depreciation for 10 years, with the latest figure at $869000.0 in Q4 2025.
- Quarterly Accumulated Depreciation fell 33.87% year-over-year to $869000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $869000.0 (down 33.87% YoY) and the FY2025 annual result came in at $869000.0, down 33.87% from the prior year.
- Accumulated Depreciation fell to $869000.0 in Q4 2025 per KALA's latest filing, from $1.3 million in the prior quarter.
- Over five years, Accumulated Depreciation peaked at $2.9 million in Q4 2021 and troughed at $869000.0 in Q4 2025.
- A 5-year average of $1.5 million and a median of $1.2 million in 2022 frame the typical range for Accumulated Depreciation.
- The sharpest annual moves came in 2022 and 2024: Accumulated Depreciation slumped 57.22% in 2022, then gained 18.38% in 2024.
- Over 5 years, Accumulated Depreciation stood at $2.9 million in 2021, then plunged by 57.22% to $1.2 million in 2022, then slipped by 9.31% to $1.1 million in 2023, then rose by 18.38% to $1.3 million in 2024, then plunged by 33.87% to $869000.0 in 2025.
- According to Business Quant data, Accumulated Depreciation over the past three periods registered $869000.0, $1.3 million, and $1.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 869,000.00 |
| Dec 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | 1.11 Mn |
| Dec 31, 2022 | 1.22 Mn |
| Dec 31, 2021 | 2.86 Mn |
| Dec 31, 2020 | 3.42 Mn |
| Dec 31, 2019 | 2.52 Mn |
| Dec 31, 2018 | 1.82 Mn |
| Dec 31, 2017 | 1.54 Mn |
| Dec 31, 2016 | 1.32 Mn |